IP Library Granted Patent US 7,968,594
Granted Patent B2
US 7,968,594 · App. 11/115,983 · Granted Jun 28, 2011

Pharmaceutical compositions for the treatment of pain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,594
App. No.
11/115,983
Granted
Jun 28, 2011
Kind
B2
Abstract

The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.

Claims (14)

1. A method of treatment of cancer related pain comprising administering to a subject in need thereof a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), wherein the ratio of CBD:THC by weight is 0.93:1.

2. A method of treatment of cancer related pain as claimed in claim 1 , wherein the cancer related pain is caused by cancer of the breast; cancer of the prostate; cancer of the lung; cancer of the cervix; cancer of the rectum; cancer of the stomach; or cancer of the colon.

3. A method of treatment of cancer related pain as claimed in claim 1 , wherein the cannabinoids are packaged for delivery in a titratable dosage form.

4. A method of treatment of cancer related pain as claimed in claim 1 , wherein the cannabinoid CBD is administered separately, simultaneously or sequentially to the cannabinoid THC.

5. A method of treatment of cancer related pain as claimed in claim 1 , wherein a unit dose taken by a patient is in the range of about 5-25 mg of each cannabinoid.

6. A method of treatment of cancer related pain as claimed in claim 1 , wherein the maximum daily dosage dose of each cannabinoid is less than or equal to about 120 mg of CBD and less than or equal to about 130 mg of THC.

7. A method of treatment of cancer related pain as claimed in claim 1 , wherein the cannabinoids are packaged for delivery such that delivery is targeted to a sublingual area; a buccal area; an oral area; a rectal area, a nasal area; and/or the pulmonary system.

8. A method of treatment of cancer related pain as claimed in claim 7 , wherein the cannabinoids are in a gel form; a gel spray form; a tablet form; a liquid form; a capsule form; or a form for vaporisation.

9. A method of treatment of cancer related pain as claimed in claim 1 , wherein the cannabinoids are present as a cannabis based medicine extract (CBME).

10. A method of treatment of cancer related pain as claimed in claim 1 , wherein the combination of cannabinoids comprises:

a) a cannabis based medicinal extract which comprises THC at more than 90% of the total cannabinoid content in the extract; and

b) a cannabis based medicinal extract which comprises CBD at more than 90% of the total cannabinoid content in the extract.

11. A method of treatment of cancer related pain as claimed in claim 1 , wherein the cannabinoids are substantially pure.

12. A method of treatment of cancer related pain as claimed in claim 1 , wherein the cannabinoids are synthetic.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2026
From: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
To: CNX THERAPEUTICS LIMITED
Reel/Frame 073691/0141 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2025
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED (F/K/A GW PHARMA LIMITED); JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
Reel/Frame 072747/0876 →
CHANGE OF NAME Recorded May 13, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071097/0142 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
DEED OF ASSIGNMENT OF INTELLECTUAL PROPERTY RIGHTS Recorded Feb 4, 2021
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 055222/0457 →